Ghassan Riachi

5.5k total citations
36 papers, 554 citations indexed

About

Ghassan Riachi is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Ghassan Riachi has authored 36 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hepatology, 11 papers in Epidemiology and 7 papers in Rheumatology. Recurrent topics in Ghassan Riachi's work include Hepatitis C virus research (14 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Liver Disease Diagnosis and Treatment (8 papers). Ghassan Riachi is often cited by papers focused on Hepatitis C virus research (14 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Liver Disease Diagnosis and Treatment (8 papers). Ghassan Riachi collaborates with scholars based in France, Egypt and United States. Ghassan Riachi's co-authors include Philippe Ducrotté, Éric Lerebours, Odile Goria, R Colín, Odile Goria, Michel Scotté, Fabien Zoulim, Guillaume Savoye, Emmanuel Huet and Arnaud François and has published in prestigious journals such as The Lancet, Journal of Hepatology and Annals of Oncology.

In The Last Decade

Ghassan Riachi

34 papers receiving 534 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ghassan Riachi France 13 332 297 100 72 72 36 554
Valentina Cossiga Italy 15 254 0.8× 323 1.1× 74 0.7× 19 0.3× 28 0.4× 43 521
Chi‐Jen Chu Taiwan 18 773 2.3× 764 2.6× 178 1.8× 69 1.0× 23 0.3× 58 1.0k
Delphine Weil France 12 370 1.1× 355 1.2× 134 1.3× 9 0.1× 24 0.3× 36 566
Thinesh Lee Krishnamoorthy Singapore 9 154 0.5× 151 0.5× 65 0.7× 35 0.5× 96 1.3× 25 375
Y. T. Tsai Taiwan 15 400 1.2× 387 1.3× 245 2.5× 210 2.9× 12 0.2× 33 792
Jorge Delgado Israel 15 112 0.3× 188 0.6× 138 1.4× 14 0.2× 52 0.7× 36 603
Bandar Al-Judaibi Canada 12 251 0.8× 209 0.7× 155 1.6× 29 0.4× 7 0.1× 27 443
Wikrom Karnsakul United States 12 198 0.6× 148 0.5× 135 1.4× 9 0.1× 34 0.5× 62 472
Vincents J. Dindzans United States 14 595 1.8× 480 1.6× 302 3.0× 48 0.7× 7 0.1× 31 870
G Theocharis Greece 7 302 0.9× 309 1.0× 110 1.1× 102 1.4× 8 0.1× 13 485

Countries citing papers authored by Ghassan Riachi

Since Specialization
Citations

This map shows the geographic impact of Ghassan Riachi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ghassan Riachi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ghassan Riachi more than expected).

Fields of papers citing papers by Ghassan Riachi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ghassan Riachi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ghassan Riachi. The network helps show where Ghassan Riachi may publish in the future.

Co-authorship network of co-authors of Ghassan Riachi

This figure shows the co-authorship network connecting the top 25 collaborators of Ghassan Riachi. A scholar is included among the top collaborators of Ghassan Riachi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ghassan Riachi. Ghassan Riachi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Allaire, Manon, Julien Edeline, P. Merle, et al.. (2025). 1487P Extended follow-up at 42 months of atezolizumab–bevacizumab in advanced HCC: Insights from the CHIEF prospective study. Annals of Oncology. 36. S829–S829.
2.
Bronowicki, J.-P., Patrick Miailhes, Denis Ouzan, et al.. (2022). An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir–grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study). Health Science Reports. 6(1). e619–e619. 1 indexed citations
3.
Dorival, Céline, Carole Cagnot, Hélène Fontaine, et al.. (2022). Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. Clinics and Research in Hepatology and Gastroenterology. 46(6). 101923–101923. 14 indexed citations
4.
Sefrioui, David, Céline Savoye‐Collet, Ludivine Beaussire, et al.. (2020). 1007P cfDNA and ctDNA variations are predictive of disease progression to conventional transarterial chemoembolization (cTACE) in patients with hepatocellular carcinoma (HCC). Annals of Oncology. 31. S698–S698. 1 indexed citations
5.
Jouve, Jean–Louis, Thierry Lecomte, Olivier Bouché, et al.. (2019). Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. Journal of Hepatology. 71(3). 516–522. 82 indexed citations
6.
Marcellin, Patrick, Fabien Zoulim, Christophe Hézode, et al.. (2016). Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. Digestive Diseases and Sciences. 61(10). 3072–3083. 48 indexed citations
7.
Dominique, S., Michaël Eliezer, Muriel Quillard, et al.. (2016). Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease?. Canadian Respiratory Journal. 2016. 1–8. 7 indexed citations
8.
Schwarz, Lilian, Michaël Bubenheim, Isabelle Gardin, et al.. (2016). Adjuvant I‐131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma. World Journal of Surgery. 40(8). 1941–1950. 5 indexed citations
9.
Duval-Modeste, Anne-Bénédicte, P. Joly, Nathalie Massy, et al.. (2013). First case of drug rash eosinophilia and systemic symptoms due to boceprevir. Journal of Hepatology. 60(4). 891–893. 11 indexed citations
10.
Brochot, Étienne, Ghassan Riachi, Jean‐Christophe Plantier, et al.. (2013). Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C. Journal of Medical Virology. 85(7). 1191–1198. 1 indexed citations
11.
Brunel, Valéry, B Cauliez, L. Lacaze, et al.. (2011). Liver mass in a young adult. The Lancet. 378(9797). 1196–1196. 6 indexed citations
12.
Bernard, Mathieu, Isabelle Marié, Ghassan Riachi, et al.. (2005). Inflammatory pseudotumor of the liver revealing gynecologicalCorynebacteriuminfection. Scandinavian Journal of Gastroenterology. 40(7). 875–877. 3 indexed citations
13.
Marie, I., Philippe Ducrotté, Ghassan Riachi, et al.. (2004). CASE REPORT: Pseudo-Angiocholitis Revealing Adult-Onset Still's Disease. Digestive Diseases and Sciences. 49(4). 627–628. 2 indexed citations
14.
Hervé, Sophie, Guillaume Savoye, Ghassan Riachi, et al.. (2001). Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity?. European Journal of Gastroenterology & Hepatology. 13(5). 495–500. 30 indexed citations
15.
Hézode, C., Françoise Roudot‐Thoraval, Sylvie Naveau, et al.. (2000). Alpha 2A interferon monotherapy in patients with chronic hepatitis C and repeatedly normal aminotransferase levels. Journal of Hepatology. 32. 109–109. 1 indexed citations
16.
Naveau, Sylvie, Axel Balian, Françoise Degos, et al.. (1999). Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Journal of Hepatology. 31(4). 612–617. 11 indexed citations
17.
Poynard, Thierry, Sylvie Chevret, J. Moussalli, et al.. (1999). A short induction regimen of interferon‐α is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. Journal of Viral Hepatitis. 6(5). 381–386. 6 indexed citations
18.
Degos, Françoise, Sylvie Chevret, Anne Bastie, et al.. (1998). Reinforced regiment of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomized trial. Journal of Hepatology. 29(2). 224–232. 23 indexed citations
19.
Hochain, Patrick, V. Merle, C. Capet, et al.. (1996). [Upper digestive hemorrhage in patients over 80 years of age: incidence and prognostic factors].. PubMed. 20(8-9). 638–44. 5 indexed citations
20.
Riachi, Ghassan, Philippe Ducrotté, C Guédon, et al.. (1996). Duodenojejunal Motility After Oral and Enteral Nutrition in Humans: A Comparative Study. Journal of Parenteral and Enteral Nutrition. 20(2). 150–155. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valentina Cossiga Breakdown of academic impact, for papers by Chi‐Jen Chu Breakdown of academic impact, for papers by Delphine Weil Breakdown of academic impact, for papers by Thinesh Lee Krishnamoorthy Breakdown of academic impact, for papers by Y. T. Tsai Breakdown of academic impact, for papers by Jorge Delgado Breakdown of academic impact, for papers by Bandar Al-Judaibi Breakdown of academic impact, for papers by Wikrom Karnsakul Breakdown of academic impact, for papers by Vincents J. Dindzans Breakdown of academic impact, for papers by G Theocharis
Rankless by CCL
2026